- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04037332
Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda (Caramal DRM)
Monitoring of Molecular Markers of Artemisinin Resistance in Plasmodium Falciparum Malaria: Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
Currently, 16 African countries include the use of pre-referral rectal artesunate (RAS) in their treatment policies. However, guidelines for RAS use vary widely across countries and inappropriate use of RAS as a monotherapy and consequential development of resistances against artemisinin based treatments is of particular concern.
In the frame of the Unitaid-funded "Community Access to Rectal Artesunate for Malaria" (CARAMAL) Project, quality-assured RAS will be rolled in selected areas of the Democratic Republic of the Congo (DRC), Nigeria and Uganda. Approximately 3,000 treatments of RAS will be dispensed by trained community health workers to children <5 years of age in each project country per year.
Linked to the tracking of (severe) malaria patients in the frame of the CARAMAL project, this study will assess the frequency of artemisinin resistance markers in the study settings and tentatively assess whether the introduction of RAS could increase the selection of resistant P. falciparum strains. The study will be conducted in close collaboration with the Global Malaria Programme of the WHO. Finger-prick blood samples will be collected from children < 5 years of age with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities before and after the pilot roll-out of pre-referral RAS at community level.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Currently, 16 African countries include the use of pre-referral rectal artesunate (RAS) in their treatment policies and a number of countries have begun to implement RAS. However, guidelines for RAS use vary widely across countries and often do not align with WHO recommendations. Of particular concern in this context is the inappropriate use of RAS as a monotherapy (i.e. without subsequent ACT treatment).
In the frame of the Unitaid-funded "Community Access to Rectal Artesunate for Malaria" (CARAMAL) Project, quality-assured (QA) RAS will be rolled out through integrated Community Case Management (iCCM) schemes in selected areas of the Democratic Republic of the Congo (DRC), Nigeria and Uganda. The goal of the CARAMAL Project is to contribute to reducing malaria mortality in children by improving the community management of suspected severe malaria cases. The project will contribute to this goal by advancing the development of operational guidance to catalyse effective and appropriate scale-up of quality-assured rectal artesunate (RAS) as pre-referral treatment of severe malaria.
In the frame of the CARAMAL project, approximately 3,000 treatments of RAS will be dispensed by trained community health workers to children <5 years of age in each project country per year. Children treated with pre-referral RAS will be referred to a higher-level health facility for comprehensive clinical management, including the administration of a full course of an artemisinin-based combination therapy, as per WHO guidelines.
While phenotypic resistance of the Plasmodium parasites against artemisinin has not yet been document in the study settings, this potential threat is a major concern. The administration of artemisinin monotherapies increases drug pressure, which may lead to the selection of drug resistance conferring mutations. Mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domains are the currently known major determinant of partial resistance against artemisinin. Data on artemisinin resistance of Plasmodium parasites in the CARAMAL Project countries are patchy. K13-propeller polymorphisms previously reported from Cambodia have been found e.g. in parasites from northern Uganda, but the mutations linked to artemisinin resistance were uncommon and did not seem to increase over time. The general notion is that numerous K13 polymorphisms circulate in Africa but their distribution does not currently support the spread of artemisinin resistance.
Linked to the tracking of (severe) malaria patients in the frame of the CARAMAL project, this study will assess the frequency of artemisinin resistance markers in the study settings and tentatively assess whether the introduction of RAS could increase the selection of resistant P. falciparum strains. The study will be conducted in close collaboration with the Global Malaria Programme of the WHO. Finger-prick blood samples will be collected from children < 5 years of age with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities before and after the pilot roll-out of pre-referral RAS at community level.
Dried blood spots on filter papers will be sent to a WHO-chosen laboratory (Malaria Molecular Epidemiology Unit at the Pasteur Institute in Cambodia) for molecular analyses to assess the presence of markers of artemisinin resistance (K13-propeller sequence polymorphisms).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Kwango
-
Kenge, Kwango, Congo, The Democratic Republic of the
- Health Zone of Kenge
-
-
Kwilu
-
Ipamu, Kwilu, Congo, The Democratic Republic of the
- Health Zone of Ipamu
-
Kingandu, Kwilu, Congo, The Democratic Republic of the
- Health Zone of Kingandu
-
-
-
-
Adamawa
-
Yola, Adamawa, Nigeria
- Adamawa State, selected LGAs
-
-
-
-
Apac
-
Lira, Apac, Uganda
- Apac District
-
-
Kole
-
Lira, Kole, Uganda
- Kole District
-
-
Oyam
-
Lira, Oyam, Uganda
- Oyam District
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age below 5 years
- enrolled in CARAMAL Project
- history of fever plus danger signs indicative of severe febrile illness / suspected severe malaria, according to local iCCM guidelines
- positive malaria test result by RDT or microscopy
- written informed consent from a parent or guardian
Exclusion Criteria:
- no current malaria infection
- mixed or mono-infection with a non-P. falciparum species known prior to sample collection
- no permanent residence in project area
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pre-RAS roll-out . Group I
I. Children presenting directly to a referral health facility without prior administration of RAS (pre-RAS): provides a baseline assessment of artemisinin resistance marker prevalence before the introduction of RAS
|
Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
|
Post-RAS roll-out - Group II
II. Children presenting directly to a referral health facility without prior administration of RAS (post-RAS): group not receiving pre-referral RAS and hence having baseline pressure for K13 resistance markers.
|
Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
|
Post-RAS roll-out - Group III
III. Children receiving pre-referral RAS from community-based provider and successfully referred to a referral health facility: group receiving pre-referral RAS (monotherapy).
|
Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
|
Post-RAS roll-out - Group IV
IV. Children receiving pre-referral RAS from community-based provider but not completing referral to a referral health facility, followed-up at their home on day 28: children malaria-positive on Day 28 may have an increased chance of harboring a resistant infection.
|
Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
K13-propeller sequence polymorphisms in P. falciparum
Time Frame: Through study completion, up to one year
|
Prevalence of molecular markers of artemisinin resistance in P. falciparum, namely K13-propeller sequence polymorphisms - before, after introduction of RAS in respective study area
|
Through study completion, up to one year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christian Burri, Swiss TPH, Department of Medicine
- Principal Investigator: Christian Lengeler, PhD, Swiss TPH, Department of Epidemiology and Public Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P 001-18-2.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Malaria
-
Novartis PharmaceuticalsWellcome Trust; European and Developing Countries Clinical Trials Partnership...RecruitingSevere MalariaBurkina Faso, India, Rwanda, Congo, The Democratic Republic of the, Gabon, Nigeria, Côte D'Ivoire, Kenya
-
University of OxfordCompletedSevere Falciparum MalariaBangladesh
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome TrustSuspendedSevere Falciparum MalariaIndonesia
-
Institute of Tropical Medicine, BelgiumKU Leuven; Leiden University Medical Center; Barcelona Institute for Global Health and other collaboratorsRecruitingUncomplicated Malaria | Severe Malaria | Asyptomatic Plasmodium InfectionMozambique, Belgium, Burkina Faso
-
Dr Fabrice BRUNEELCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedMalaria | Severe MalariaMali
-
University of OxfordUniversity of Kinshasa; Mahidol Oxford Tropical Medicine Research UnitCompletedSevere MalariaCongo, The Democratic Republic of the
-
Swiss Tropical & Public Health InstituteMedicines for Malaria VentureCompletedSevere MalariaCongo, The Democratic Republic of the
-
Makerere UniversityUnknown
-
National Institute of Allergy and Infectious Diseases...CompletedMalaria | Severe Malaria | Antimalarial Drug ResistanceCambodia